Recent advances in biochemical diagnosis and assessment of severity in acute pancreatitis

Serum amylase is most commonly used as a biochemical marker of acute pancreatitis (AP). But it lacks specificity. The serum lipase level is more accurate and a better marker. Serum elastase -1 level is specific and remains elevated longer, but its radioimmunoassay is not routinely used. Recently, it can be rapidly measured by latex turbidometric immunoassay with automatic analyzer. Biochemically, only CRP test is available and useful to assess severity, but its sensitivity is unacceptably low in the early course of the disease. Urinary trypsinogen activation peptide (TAP) or trypsinogen-2 is an earlier marker. Increasing knowledge of the inflammatory process in AP has led to possibly useful biochemical indicators of severity, such as cytokines, nonpancreatic synovial type group II PLA2 or granulocyte elastase.     

Tosulfoxacin treatment ofChlamydia trachomatis infection of the uterine cervix

In vivo efficacy of tosufloxacin (TFLX) for treatment ofChlamydia trachomatis cervical infection in women was evaluated by enzyme immunoassay. The short term (within 31 days of treatment) response rates with a dosage of 150 mg orally 3 times daily were 100% (54/54) with 14 days of treatment and 97% (38/39) with 7 days of treatment. Subjective symptoms such as lower abdominal pain, vaginal discharge, or atypical bleeding were observed in 76 (82%) of the 93 patients. After treatment, symptoms improved in 75 (99%) of 76 patients. Two of 34 patients (5.9%) showed positive results in the long interval tests (1 to 18 months after treatment). Three (2.3%) of 131 patients needed to be changed from TFLX to other drugs due to side effects (eczema, face edema, urticaria). TFLX was effective and patients showed high compliance for treatment of cervicalC. trachomatis infection.